| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Onjisaponin F targets multiple biological pathways including inflammatory signaling and immune responses. The compound exhibits anti-inflammatory effects through inhibition of pro-inflammatory cytokine production and modulation of NF-κB signaling. Its immunomodulatory activity involves modulation of immune cell function. The compound may also exhibit neuroprotective and anticancer activities through modulation of various signaling pathways.
|
|---|---|
| ln Vitro |
In nasal washes, polygalasaponin XXXI (Onjisaponin F) also increased anti-HA IgA and IgG Ab titers, but Onjisaponins E and G only considerably increased anti-HA IgA Ab titers. Intranasal influenza virus infection can be prevented by protective immunity induced by polygala saponin XXXI [1]. Rat basal forebrain cells are also induced to express ChAT mRNA by Polygalasaponin XXXI (Onjisaponin F) at concentrations of 1 or 10 µg/mL [2].
In vitro, onjisaponin F exhibits anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines. It demonstrates immunomodulatory activity by modulating immune cell function. The compound may also show neuroprotective activity in neuronal cell models and anti-cancer activity by inducing apoptosis in cancer cell lines. Its effects on cell signaling pathways have been characterized in various cellular models. |
| ln Vivo |
The multiplication of the mouse-adapted influenza virus A/PR/8/34 in the bronchoalveolar lavage fluid of infected mice is inhibited by the intranasal inoculation of Polygala saponin XXXI (Onjisaponin F) [1].
In vivo studies on onjisaponin F are limited. Based on its mechanism of action, the compound may have potential in inflammatory disorders, neurodegenerative diseases, and cancer. Its anti-inflammatory, immunomodulatory, and neuroprotective properties suggest potential therapeutic applications. Further in vivo studies are needed to fully characterize its pharmacological effects and therapeutic potential. |
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, onjisaponin F can be evaluated for its effects on inflammatory mediators. Cell-free assays can be performed to assess inhibition of COX-2 or iNOS activity. The compound is incubated with the enzyme and substrate, and activity is measured using colorimetric or fluorometric detection. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, onjisaponin F is typically tested on immune cells, neuronal cells, or cancer cell lines. Cells are treated with the compound at various concentrations (typically 1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Cytokine production is measured by ELISA. Apoptosis is evaluated by flow cytometry. Neuroprotective effects are assessed in models of oxidative stress. Signaling pathway modulation is assessed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for onjisaponin F have not been extensively reported. Based on its anti-inflammatory, immunomodulatory, and neuroprotective activities, potential experimental models include inflammation models, neurodegeneration models, and cancer models in mice or rats. The compound could be administered orally or intraperitoneally, with relevant biomarkers assessed as pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for onjisaponin F are limited. As a saponin with multiple sugar moieties, it is expected to have low oral bioavailability due to poor absorption. The compound may be metabolized in the gastrointestinal tract. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for onjisaponin F are limited. As a natural product isolate, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References |
|
| Additional Infomation |
Onjisaponin F is a triterpenoid saponin. It has been reported that Onjisaponin F exists in Polygala tenuifolia and Polygala jasminoides, and relevant data are available for reference.
Onjisaponin F is a research-use only compound and has not been approved for clinical applications. It is a saponin natural product. Its molecular weight and formula are well-characterized. It is available from various research chemical suppliers. Further research is needed to fully elucidate its pharmacological profile and therapeutic potential. |
| Molecular Formula |
C75H112O36
|
|---|---|
| Molecular Weight |
1589.6702
|
| Exact Mass |
1588.693
|
| CAS # |
79103-90-5
|
| PubChem CID |
10701737
|
| Appearance |
White to off-white solid
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.651
|
| LogP |
4.95
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
36
|
| Rotatable Bond Count |
24
|
| Heavy Atom Count |
111
|
| Complexity |
3260
|
| Defined Atom Stereocenter Count |
36
|
| SMILES |
C([C@@]12CC[C@]3(CCC(C[C@H]3C1=CC[C@@H]1[C@]3(C[C@H](O)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@](C)(C(=O)O)[C@@H]3CC[C@@]21C)C)(C)C)C(=O)O[C@@H]1O[C@H](C)[C@H](OC(=O)/C=C/C2C=C(OC)C(OC)=C(OC)C=2)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O[C@@H]2OC[C@@H](O)[C@H](O[C@@H]3OC[C@H](O)[C@H](O)[C@H]3O)[C@H]2O)[C@@H](O[C@@H]2OC[C@](O)(CO)[C@H]2O)[C@H]1O)O
|
| InChi Key |
HDLNHPZHTNFCNP-JJEFWQELSA-N
|
| InChi Code |
InChI=1S/C75H112O36/c1-31-53(105-44(82)14-11-33-21-39(96-8)56(98-10)40(22-33)97-9)50(88)58(109-64-52(90)57(108-66-59(91)75(95,29-78)30-101-66)54(32(2)102-64)106-62-51(89)55(38(81)27-100-62)107-61-48(86)45(83)37(80)26-99-61)65(103-31)111-68(94)73-18-17-69(3,4)23-35(73)34-12-13-42-70(5)24-36(79)60(110-63-49(87)47(85)46(84)41(25-76)104-63)72(7,67(92)93)43(70)15-16-71(42,6)74(34,28-77)20-19-73/h11-12,14,21-22,31-32,35-38,41-43,45-55,57-66,76-81,83-91,95H,13,15-20,23-30H2,1-10H3,(H,92,93)/b14-11+/t31-,32+,35+,36+,37+,38-,41-,42-,43-,45+,46-,47+,48-,49-,50+,51-,52-,53+,54+,55+,57+,58-,59+,60+,61+,62+,63+,64+,65+,66+,70-,71-,72+,73+,74+,75-/m1/s1
|
| Chemical Name |
(2S,3R,4S,4aR,6aR,6bR,8aS,12aS,14aR,14bR)-8a-[(2S,3R,4S,5R,6R)-3-[(2S,3R,4S,5S,6S)-4-[(2S,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-5-[(2S,3R,4S,5R)-3,5-dihydroxy-4-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyl-5-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxyoxan-2-yl]oxycarbonyl-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid
|
| Synonyms |
Polygalasaponin XXXI
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~31.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (0.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (0.79 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 1.25 mg/mL (0.79 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6291 mL | 3.1453 mL | 6.2906 mL | |
| 5 mM | 0.1258 mL | 0.6291 mL | 1.2581 mL | |
| 10 mM | 0.0629 mL | 0.3145 mL | 0.6291 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
